Literature DB >> 19786994

Serum free light chain assessment in monoclonal gammopathy and kidney disease.

Colin A Hutchison1, Kolitha Basnayake, Paul Cockwell.   

Abstract

Abnormalities of immunoglobulin free light chains (FLCs) are frequently present in patients with monoclonal gammopathies and can cause kidney disease. The recent introduction of highly sensitive immunoassays that measure FLCs to levels below those present in normal individuals has provided a new tool for diagnosis and management in this setting. Here, we review the biology of FLC production in health and disease, and the utility of FLC immunoassays in the assessment of monoclonal gammopathies in kidney disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19786994     DOI： 10.1038/nrneph.2009.151

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  55 in total

1.  Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements.

Authors:  Godelieve Mariën; Els Oris; Arthur R Bradwell; Norbert Blanckaert; Xavier Bossuyt
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

2.  Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Authors:  Colin A Hutchison; Paul Cockwell; Steven Reid; Katie Chandler; Graham P Mead; John Harrison; John Hattersley; Neil D Evans; Mike J Chappell; Mark Cook; Hermann Goehl; Markus Storr; Arthur R Bradwell
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

3.  Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease.

Authors:  S Déret; J Chomilier; D B Huang; J L Preud'homme; F J Stevens; P Aucouturier
Journal:  Protein Eng       Date:  1997-10

4.  Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.

Authors:  Peter G Hill; Julia M Forsyth; Baldeep Rai; Stewart Mayne
Journal:  Clin Chem       Date:  2006-07-20       Impact factor: 8.327

5.  Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.

Authors:  Masayuki Matsuda; Toshiyuki Yamada; Takahisa Gono; Yasuhiro Shimojima; Wataru Ishii; Tomohisa Fushimi; Kazuo Sakashita; Kenichi Koike; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2005-05       Impact factor: 1.271

Review 6.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

7.  Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta.

Authors:  L Zhu; G A Herrera; J E Murphy-Ullrich; Z Q Huang; P W Sanders
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

8.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

9.  Screening panels for detection of monoclonal gammopathies.

Authors:  Jerry A Katzmann; Robert A Kyle; Joanne Benson; Dirk R Larson; Melissa R Snyder; John A Lust; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Clin Chem       Date:  2009-06-11       Impact factor: 8.327

10.  Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report.

Authors:  Kolitha Basnayake; Colin Hutchison; Dia Kamel; Michael Sheaff; Neil Ashman; Mark Cook; Heather Oakervee; Arthur Bradwell; Paul Cockwell
Journal:  J Med Case Rep       Date:  2008-12-09
View more
  10 in total

Review 1.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

2.  Homogeneous immunosubtraction integrated with sample preparation enabled by a microfluidic format.

Authors:  Akwasi A Apori; Amy E Herr
Journal:  Anal Chem       Date:  2011-03-04       Impact factor: 6.986

3.  Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD.

Authors:  James Ritchie; Lakhvir K Assi; Anne Burmeister; Richard Hoefield; Paul Cockwell; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

4.  Serum free light chains and the risk of ESRD and death in CKD.

Authors:  Richard Haynes; Colin A Hutchison; Jonathan Emberson; Tanaji Dasgupta; David C Wheeler; John N Townend; Martin J Landray; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

5.  The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.

Authors:  B Talbot; D Wright; K Basnayake
Journal:  BMJ Case Rep       Date:  2014-10-17

6.  Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains in multiple myeloma-induced kidney injury.

Authors:  F P Tillmann
Journal:  Indian J Nephrol       Date:  2015 Jul-Aug

7.  The value of serum immunoglobulin free light chain assessment in patients with monoclonal gammopathies and acute renal failure.

Authors:  Mustafa Cirit; Atilla Uzüm; Pınar Ozen; Banu A Sentürk; Giray Bozkaya; Bahriye Payzin; Orçun Ural
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

8.  Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients.

Authors:  Ben Sprangers; Kathleen Claes; Pieter Evenepoel; Dirk Kuypers; Koen Poesen; Michel Delforge; Xavier Bossuyt V; Björn Meijers
Journal:  Kidney Int Rep       Date:  2020-01-30

9.  Light chain myeloma and detection of free light chains in serum and urine of dogs and cats.

Authors:  Robert Adam Harris; Matthew Miller; Dillon Donaghy; Laura Ashton; Catherine Langston; Todd Shockey; A Russell Moore
Journal:  J Vet Intern Med       Date:  2021-02-26       Impact factor: 3.333

Review 10.  Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management.

Authors:  Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela V Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.